Forward BIOLABS Announces Round 1 Awardees of the Innovation to Commercialization Pipeline (ICP) Program
Forward BIOLABS, in partnership with BioForward Wisconsin, is pleased to announce the Round 1 awardees of the Innovation to Commercialization Pipeline (ICP) program. Eighteen emerging biohealth companies across Wisconsin have been selected to receive ICP awards. Awardees span a broad range of Wisconsin’s biohealth sectors, including biomanufacturing, diagnostics, life sciences, medical devices, pharmaceuticals, and radiopharmaceuticals.
Wisconsin’s biohealth sector is a cornerstone of the state’s economy, generating billions in economic activity and supporting a broad spectrum of high-skill, high-impact jobs across research, manufacturing, and healthcare. Sustaining that momentum depends on a strong pipeline of new companies capable of translating innovation into commercial success. The Innovation to Commercialization Pipeline (ICP) program strengthens that pipeline, providing early-stage biohealth companies with the targeted support needed to reduce risk, position themselves to attract additional investment, and grow into the next generation of Wisconsin-based industry leaders.
